Skip to main content
Clinical Trials/JPRN-UMIN000027441
JPRN-UMIN000027441
Completed
未知

The clinical trial for safety and efficacy of chronic hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1) - Hepatitis therapeutics agent, 3-oxygelmillpropionic acid polymer for pancreatic cancer (Phase 1)

Osaka University0 sites10 target enrollmentMay 23, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Resectable pancreatic cancer
Sponsor
Osaka University
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 23, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Patients who could not resected curatively.(2\)Patients with active double cancer. (3\)Patients with serious drug hypersensitivity or with a history of drug allergy.(4\)Patients with serious complications.(5\)Patients with jaundice,cirrhosis or with suspected cirrhosis of the liver.(6\)There is a history of chronic hepatitis B, and in the present study drug has already been ingested.(7\)Patients with active infection.(8\)Women who have a possibility of or in the pregnancy,who hope to become pregnant,or who are breast\-feeding. Men who wish to become pregnant partner.(9\)Patients with severe mental disorder.(10\)Other patients whom the physician decided to be unsuitable for safely carrying out the present study.

Outcomes

Primary Outcomes

Not specified

Similar Trials